AI Article Synopsis

  • Distant metastasis in differentiated thyroid carcinoma (DTC) is rare but can impact prognosis; this study focused on long-term outcomes of lung metastasis in DTC patients.
  • A retrospective analysis of 4572 DTC patients revealed 152 with lung metastasis, with 10- and 20-year survival rates of 85.0% and 71.0%, respectively; factors like older age, larger tumor size, and (131)I nonavidity correlated with poorer outcomes.
  • The findings suggest that while the prognosis for lung metastasis is generally favorable, (131)I nonavidity is a significant independent predictor of poor prognosis in these patients.

Article Abstract

Background: Distant metastasis, generally to lung and bone, is rare in differentiated thyroid carcinoma (DTC) and the prognosis is still elusive. We investigated long-term outcomes of lung metastasis in DTC patients and its prognostic factors.

Methods: A retrospective review was performed of 4572 patients who underwent surgery for DTC from 1962 to 2009 at Seoul National University Hospital. Among them, 164 patients were identified with lung metastasis and 152 patients were enrolled in the final analysis. Poor prognosis was defined as progressive disease or death.

Results: Of these 152 patients, 10- and 20-year survival rates were 85.0% and 71.0%, respectively. No evidence of disease, stable disease, progressive disease, and death was identified in 22.4%, 28.3%, 35.5%, and 13.8%, respectively, after 11 years of median follow-up (range 2-41 years). Older age at diagnosis (≥45 years), primary tumor size ≥2 cm, follicular thyroid cancer, metastasis diagnosed after initial evaluation or (131)I remnant ablation (late metastasis), multiple metastases other than lung, (131)I nonavidity, and the presence of macronodules (≥1 cm) were more frequent in poor prognoses. Cox proportional hazard ratio for progression-free survival showed that (131)I nonavidity was the only independent predictive factor for poor prognosis.

Conclusions: The prognosis of lung metastasis from DTC in Korea within this study was favorable. (131)I nonavidity, observed more frequently in late metastasis, was the only independent factor predicting poor prognosis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926138PMC
http://dx.doi.org/10.1089/thy.2012.0654DOI Listing

Publication Analysis

Top Keywords

lung metastasis
16
131i nonavidity
12
differentiated thyroid
8
thyroid cancer
8
metastasis
8
metastasis dtc
8
152 patients
8
poor prognosis
8
progressive disease
8
late metastasis
8

Similar Publications

ABCF1-K430-Lactylation promotes HCC malignant progression via transcriptional activation of HIF1 signaling pathway.

Cell Death Differ

January 2025

Department of Hepatobiliary Surgery of the affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, China.

Lysine lactylation plays critical roles in various diseases, including cancer. Our previous study showed that lactylation of non-histone ABCF1 may be involved in hepatocellular carcinoma (HCC) progression. In this study, we evaluated the prognostic value of ABCF1-K430la in HCC using immunohistochemical staining and performed amino acid point mutations, multi-omics crossover, and biochemical experiments to investigate its biological role and underlying mechanism.

View Article and Find Full Text PDF

Introduction: Lung cancer is a major cause of cancer-related deaths, with 2 million new cases annually. Bronchopulmonary neuroendocrine tumors (BP-NETs) comprise about 20 % of lung cancers, including typical carcinoid tumors (TC). While tobacco is a primary risk factor, non-tobacco factors also play a role.

View Article and Find Full Text PDF

Objective: Interleukin-17 E (IL-17E) is a pro-inflammatory cytokine that participates in the inflammatory response and tumorigenesis. However, the function of IL-17E in non-small cell lung cancer (NSCLC) remains largely unknown.

Methods: The clinical value of IL-17E was determined by immunohistochemistry (IHC) in 75 cases of NSCLC tissues.

View Article and Find Full Text PDF

This study was aimed to evaluate the cost-effectiveness of pembrolizumab with chemotherapy (pembrolizumab combination therapy) and compare it with standard-of-care platinum-based chemotherapy (chemotherapy alone) as a first-line treatment for metastatic nonsquamous NSCLC from the perspective of Taiwan's third-party-payer public health-care system. We used a partitioned survival model with an estimated time horizon of 10 years. The partitioned survival model uses Kaplan-Meier estimates of progression-free and overall survival from the KEYNOTE-189 clinical trial.

View Article and Find Full Text PDF

This study aimed to identify radiotherapy dosimetric parameters related to local failure (LF)-free survival (LFFS) in patients with lung and liver oligometastases from colorectal cancer treated with stereotactic body radiotherapy (SBRT). We analyzed 75 oligometastatic lesions in 55 patients treated with SBRT between January 2014 and December 2021. There was no constraint or intentional increase in maximum dose.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!